(Q47566032)

4 February 2018

title

Heterogeneity of chronic obstructive pulmonary disease exacerbations: a two-axes classification proposal (English)

1 reference

4 February 2018

chronic obstructive pulmonary disease

main subject

1 reference

1 reference

Jose Luis Lopez-Campos

series ordinal

1

1 reference

4 February 2018

Alvar Agustí

series ordinal

2

1 reference

4 February 2018

publication date

9 July 2015

1 reference

4 February 2018

The Lancet. Respiratory medicine

published in

1 reference

4 February 2018

volume

3

1 reference

4 February 2018

issue

9

1 reference

4 February 2018

page(s)

729-734

1 reference

4 February 2018

COPD exacerbations: defining their cause and prevention

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

High-risk patients following hospitalisation for an acute exacerbation of COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

The cost of COPD exacerbations: a university hospital--based study in Greece.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Exacerbation phenotyping in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Exacerbation of respiratory symptoms in COPD patients may not be exacerbations of COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Exacerbations or complications? Redefining the concepts in COPD

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Mecanismos moleculares de inflamación durante las agudizaciones de la enfermedad pulmonar obstructiva crónica

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

1 reference

7 January 2021

Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Airway microbiome dynamics in exacerbations of chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

New strains of bacteria and exacerbations of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Hypothesis: does COPD have an autoimmune component?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Sputum inflammatory cell-based classification of patients with acute exacerbation of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Sputum purulence-guided antibiotic use in hospitalised patients with exacerbations of COPD

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Sputum colour and bacteria in chronic bronchitis exacerbations: a pooled analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

C-reactive protein level and microbial aetiology in patients hospitalised with acute exacerbation of COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

C-reactive protein levels predict bacterial exacerbation in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Procalcitonin as a biomarker in respiratory tract infection

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Procalcitonin Guidance of Antibiotic Therapy in Community-acquired Pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Procalcitonin vs C-reactive protein as predictive markers of response to antibiotic therapy in acute exacerbations of COPD

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Utility of serum procalcitonin values in patients with acute exacerbations of chronic obstructive pulmonary disease: a cautionary note

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Procalcitonin and C-reactive protein cannot differentiate bacterial or viral infection in COPD exacerbation requiring emergency department visits

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Comparison of diagnostic values of procalcitonin, C-reactive protein and blood neutrophil/lymphocyte ratio levels in predicting bacterial infection in hospitalized patients with acute exacerbations of COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Plasma Pro-Adrenomedullin But Not Plasma Pro-Endothelin Predicts Survival in Exacerbations of COPD

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Copeptin, C-Reactive Protein, and Procalcitonin as Prognostic Biomarkers in Acute Exacerbation of COPD

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Serum periostin: a novel biomarker for asthma management

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Periostin, a novel biomarker of TH2-driven asthma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Effects of exacerbations and seasonality on exhaled nitric oxide in COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Infections and Airway Inflammation in Chronic Obstructive Pulmonary Disease Severe Exacerbations

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Serial measurements of exhaled nitric oxide during exacerbations of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Relationship between exhaled nitric oxide and treatment response in COPD patients with exacerbations

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Time course and pattern of COPD exacerbation onset.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

The IRYSS-COPD appropriateness study: objectives, methodology, and description of the prospective cohort.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Subtypes of patients experiencing exacerbations of COPD and associations with outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Characterizing and quantifying the symptomatic features of COPD exacerbations

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

The DECAF Score: predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Development and validation of a mortality risk-adjustment model for patients hospitalized for exacerbations of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Prediction of hospitalization stay in COPD exacerbations: the AECOPD-F score.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Validation of a novel risk score for severity of illness in acute exacerbations of COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Predictive score for mortality in patients with COPD exacerbations attending hospital emergency departments

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

A clinical in-hospital prognostic score for acute exacerbations of COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Biomarkers that predict and guide therapy for exacerbations of chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

The role of nebulised budesonide in the treatment of exacerbations of COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Two different dosages of nebulized steroid versus parenteral steroid in the management of COPD exacerbations: a randomized control trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Bacteriology in acute exacerbation of chronic obstructive pulmonary disease in patients admitted to hospital

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Influence of previous use of inhaled corticoids on the development of pleural effusion in community-acquired pneumonia.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Inhaled corticosteroids and systemic inflammatory response in community-acquired pneumonia: a prospective clinical study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Necessity of amoxicillin clavulanic acid in addition to prednisolone in mild-to-moderate COPD exacerbations

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Predictors of exacerbations in chronic obstructive pulmonary disease--results from the Bergen COPD cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Determinants of between-hospital variations in outcomes for patients admitted with COPD exacerbations: findings from a nationwide clinical audit (AUDIPOC) in Spain

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Predictors of hospital admission two months after emergency department evaluation of COPD exacerbation.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Predicting outcomes following hospitalization for acute exacerbations of COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Co-morbidities and 90-day outcomes in hospitalized COPD exacerbations.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

A prediction rule to identify low-risk patients with community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

Derivation and validation of a prognostic model for pulmonary embolism

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

A new initiative on precision medicine

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900242-8

7 January 2021

10.1016/S2213-2600(15)00242-8

Identifiers

DOI

1 reference

4 February 2018

PubMed ID

26165134

1 reference

4 February 2018